News and Announcements
Dr Martin Cross Appointed Non-Executive Director at Oncosil
- Published February 27, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX: OSL) is pleased to announce the appointment of Mr Lawrence Gozlan as an independent Non-executive Director of the Company, effective from today. Mr Gozlan is a highly experienced and successful biotechnology industry professional, with particular expertise in investment management and corporate advice in the life science sector.
Mr Gozlan is currently a Director of Prana Biotechnology (ASX: PBT), a Director of Ausbiotech Ltd and a number of private healthcare companies. He holds a Bachelor of Science with Honours in microbiology and immunology from the University of Melbourne.
OncoSil Medical chairman Martin Rogers said:
“On behalf of the board of directors it is with great pleasure that we welcome the appointment of Lawrence Gozlan as a non-exec director. His proven experience and track record as a biotech investment manager will be invaluable to the Company, and we are confident his input and contribution will further strengthen the board as we continue to unlock value for investors.”
OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian biotechnology company with the aim is to provide new technologies for safer medical radiation treatments. OncoSil Medical’s lead product is OncoSil™ with the first target indication being pancreatic cancer.